etidronate has been researched along with deoxycytidine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Mabhouh, AA; Mercer, JR | 1 |
| Bosma, TB; Lam, MG; van Rijk, PP; Zonnenberg, BA | 1 |
1 trial(s) available for etidronate and deoxycytidine
| Article | Year |
|---|---|
(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Etidronic Acid; Fluorouracil; Humans; Male; Middle Aged; Prostatic Neoplasms; Radiation-Sensitizing Agents; Radioisotopes; Radiopharmaceuticals; Rhenium | 2009 |
1 other study(ies) available for etidronate and deoxycytidine
| Article | Year |
|---|---|
188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.
Topics: Animals; Bone and Bones; Bone Neoplasms; Cattle; Combined Modality Therapy; Deoxycytidine; Diphosphonates; Durapatite; Etidronic Acid; Female; Gemcitabine; Humans; In Vitro Techniques; Mice; Mice, Inbred BALB C; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Rhenium; Tissue Distribution | 2008 |